X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Timing The Knife Dr_Microbe X4 Pharmaceuticals is an intriguing healthcare company that is tackling rare diseases. X4's flagship pipeline drug is mavorixafor, an oral CXCR4 antagonist that is taking on WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections, Myelokathexis), and is expected to combat chronic neutropenia, as well as other immunodeficiency disorders. X4 is using mavorixafor to take on rare diseases, which has enoouraged the FDA to grant a few of their special designations for the regulatory pa ...